Lilly’s Prevail Signs Gene Editing Collaboration with Scribe Therapeutics for Neurological Diseases
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 5 (Table of Contents)
Published: 22 May-2023
DOI: 10.3833/pdr.v2023.i5.2786 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Prevail Therapeutics, a subsidiary of Lilly, has entered into a collaboration with Scribe Therapeutics to leverage the latter’s CRISPR technology to develop in vivo therapies for serious neurological and neuromuscular diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS